Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 10:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–17 of 17 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Dronabinol Capsules, 5 mg Clear all
Recruiting Phase 2 Interventional

Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype

NCT05269628
View directory record Official record
Conditions
Multiple Sclerosis, Sleep, Pain
Interventions
Cannabidiol (CBD), Tetrahydrocannabinol (THC), Placebo CBD, Placebo THC
Drug
Lead sponsor
Tiffany J. Braley, MD, MS
Other
Eligibility
18 Years to 65 Years
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 25, 2026, 10:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparative Bioavailability of Dronabinol Oral Solution Versus Branded Capsule 5 mg Under Fasting Conditions

NCT01448772
View directory record Official record
Conditions
Bioavailability
Interventions
Dronabinol Capsules, 5 mg, Dronabinol Oral Solution
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 25, 2012 · Synced Sep 25, 2026, 10:22 PM EDT
Withdrawn Phase 2 Interventional

Dronabinol for Agitation in Dementia Crossover Trial

NCT05612711
View directory record Official record
Conditions
Dementia Moderate, Dementia Severe, Agitation,Psychomotor, Behavioral Symptoms
Interventions
Dronabinol
Drug
Lead sponsor
Ralph H. Johnson VA Medical Center
Federal
Eligibility
55 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 4, 2024 · Synced Sep 25, 2026, 10:22 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Effects of Drugs on Stress Memories

NCT06471647
View directory record Official record
Conditions
Delta-9-tetrahydrocannabinol (THC), Stress
Interventions
delta-9-tetrahydrocannabinol (THC) (5), Placebo, delta-9-tetrahydrocannabinol (THC) (10)
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 35 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 25, 2026, 10:22 PM EDT
Recruiting Phase 2 Interventional

Combined THC and CBD for OUD and Chronic Pain

NCT06544291
View directory record Official record
Conditions
Chronic Pain, Opioid Use Disorder
Interventions
CBD 300mg, CBD 600mg, Placebo 0mg
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 25, 2026, 10:22 PM EDT
Completed Phase 2 Interventional Results available

Trial of Dronabinol Adjunctive Treatment of Agitation in Alzheimer's Disease

NCT02792257
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Dronabinol (Marinol®), Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
60 Years to 95 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
5
States / cities
Miami, Florida • Baltimore, Maryland • Belmont, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Sep 25, 2026, 10:22 PM EDT
Recruiting Phase 2 Interventional

Cannabinoid Interactions With Central and Peripheral Pain Mechanisms in Osteoarthritis of the Knee

NCT04992624
View directory record Official record
Conditions
Osteoarthritis, Knee, Osteoarthritis of the Knee
Interventions
Placebo, Cannabidiol (CBD), Tetrahydrocannabinol (Marinol® or generic equivalent (e.g., dronabinol)
Drug
Lead sponsor
Steven E Harte, PhD
Other
Eligibility
21 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 25, 2026, 10:22 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Combination of Dronabinol and Clonidine for Cannabis Dependence in Patients With Schizophrenia

NCT01598896
View directory record Official record
Conditions
Cannabis Dependence, Marijuana Dependence
Interventions
Dronabinol, Clonidine, Placebo
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 45 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Sep 25, 2026, 10:22 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Clinical Study to Evaluate the Effects of Oral Delta-9-tetrahydrocannabinol (Δ9-THC) With and Without Alcohol on Perception and Driving Performance in Healthy Adults

NCT07176208
View directory record Official record
Conditions
Cannabis, Drug Effects, Driving Performance
Interventions
5 mg Dronabinol (Marinol®) + Placebo Beverage, 10 mg Dronabinol (Marinol®) + Placebo Beverage, 5 mg Dronabinol (Marinol®) + Alcohol Beverage, 10 mg Dronabinol (Marinol®) + Alcohol Beverage, Placebo Capsule + Alcohol Beverage, Placebo Capsule + Placebo Beverage
Drug
Lead sponsor
Food and Drug Administration (FDA)
Federal
Eligibility
21 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Sep 25, 2026, 10:22 PM EDT
Completed Phase 4 Interventional Results available

Dronabinol in Total Knee Arthroplasty (TKA)

NCT04734080
View directory record Official record
Conditions
Total Knee Arthroplasty, Opioid Use
Interventions
Dronabinol 5mg Cap, Placebo oral tablet
Drug · Other
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 70 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 25, 2026, 10:22 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Comparative Bioavailability of Dronabinol Oral Solution in Healthy Volunteers

NCT02604992
View directory record Official record
Conditions
Healthy
Interventions
Treatment A, Treatment B, Treatment C
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years to 50 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 19, 2016 · Synced Sep 25, 2026, 10:22 PM EDT
Withdrawn Phase 2 Interventional

The Safety, Tolerability and Efficacy of Dronabinol, for the Treatment of Nausea and Vomiting in Familial Dysautonomia

NCT02608931
View directory record Official record
Conditions
Nausea, Vomiting, Familial Dysautonomia
Interventions
Dronabinol, Placebo
Drug · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 12, 2019 · Synced Sep 25, 2026, 10:22 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Comparison of the Analgesic Effects of Dronabinol and Smoked Marijuana in Daily Marijuana Smokers

NCT00743119
View directory record Official record
Conditions
Pain Threshold, Mood
Interventions
Placebo capsules, Inactive marijuana (0% THC), Low dose Dronabinol, High dose Dronabinol, Low THC marijuana, High THC marijuana
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 45 Years · Female only
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 10, 2017 · Synced Sep 25, 2026, 10:22 PM EDT
Completed Phase 2Phase 3 Interventional

RePOSA-Revealing the Efficacy of IHL-42X Use in Patients With OSA

NCT06146101
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
IHL-42X Low Dose, IHL-42X High Dose, Placebo, IHL-42X (Optimal Dose), Dronabinol, Acetazolamide
Drug
Lead sponsor
Incannex Healthcare Ltd
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
20
States / cities
Chula Vista, California • Long Beach, California • Upland, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2026 · Synced Sep 25, 2026, 10:22 PM EDT
Recruiting Phase 2 Interventional

DReAMzz- Dronabinol and Acetazolamide Medication for Sleep Apnea (ZZ). Dose Confirmation Crossover Study for IHL-42X in Subjects With Obstructive Sleep Apnea.

NCT07635563
View directory record Official record
Conditions
Obstructive Sleep Apnea (OSA)
Interventions
IHL-42X: 2.5 mg dronabinol + 125 mg acetazolamide, IHL-42X: 5 mg dronabinol + 125 mg acetazolamide, IHL-42X: 7.5 mg dronabinol + 125 mg acetazolamide, IHL-42X: 2.5 mg dronabinol + 250 mg acetazolamide, IHL-42X: 5 mg dronabinol + 250 mg acetazolamide, IHL-42X: 7.5 mg dronabinol + 250 mg acetazolamide, IHL-42X: 2.5 mg dronabinol + 375 mg acetazolamide, IHL-42X: 5 mg dronabinol + 375 mg acetazolamide, IHL-42X: 7.5 mg dronabinol + 375 mg acetazolamide, Placebo: Negative control
Drug
Lead sponsor
Incannex Healthcare Ltd
Industry
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
13
States / cities
Chula Vista, California • Brandon, Florida • Jacksonville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 25, 2026, 10:22 PM EDT
Completed Phase 4 Interventional Results available

Effects of Delta-9 Tetrahydrocannabinol (THC) on Retention of Memory for Fear Extinction Learning in PTSD: R61 Study

NCT03008005
View directory record Official record
Conditions
PostTraumatic Stress Disorder
Interventions
Placebo Oral Capsule, Dronabinol Cap 5 milligrams (MG), Dronabinol Cap 10 milligrams (MG)
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 50 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced Sep 25, 2026, 10:22 PM EDT
Not yet recruiting Phase 3 Interventional

Dronabinol and Epidiolex to Manage Uncontrolled Residual Symptoms of Buprenorphine Initiation Trial

NCT07148206
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Dronabinol Capsules, Epidiolex 100 mg/mL Oral Solution, Placebo Dronabinol, Placebo Epidiolex
Drug · Other
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 25, 2026, 10:22 PM EDT